Skip to main content
| News

Robots from Basel set to revolutionize surgery

27.07.2020

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Robotic endoscope tip developed by the Miracle project (img: F. Brüderli)

The Miracle (Minimally Invasive Robot-Assisted Computer-guided LaserosteotomE) project is pursuing a number of different aims, as detailed in a press release issued by the University of Basel. These include planning an operation in virtual reality, high-precision bone cutting using a smart laser saw and using 3D-printed organic implants such as a new knee joint in a minimally invasive surgical procedure. The development of the individually configurable robot needed for these applications is being supported by the Werner Siemens Foundation, which has increased its funding for the project by 12 million Swiss francs to an overall total of 27 million Swiss francs

The additional funding will be used during the second phase of the Miracle project, when the technologies developed in the first phase will be combined within a modular robot. “We are deeply grateful to the Werner Siemens Foundation for supporting our visionary project”, comments Philippe Cattin, Co-Director of both Miracle project phases and head of the Department of Biomedical Engineering (DBE) at the University of Basel. The DBE is carrying out work related to the Miracle project at the Allschwil location of the Switzerland Innovation Park Basel Area, which is operated and managed by the investment and innovation promotion agency Basel Area Business & Innovation. Unique opportunities will now be presented to Basel in its role as an innovation location. “Thanks to this financing and our expertise, we are now able to tap into huge opportunities that will open the door for robotics in surgery”, Cattin explains.

The technology developed during the first phase of the project for the planning of operations in virtual reality is already being used today. In phase two, it is to be used to help design the shape and composition of implants, with the aim thereafter being to custom manufacture these implants via a 3D printer. Cattin is therefore sharing leadership of this phase with Florian M. Thieringer, who is head of the 3D Print Lab at University Hospital Basel. “With Miracle, we don’t just want to develop a new technology but rather fully transform bone surgery,” explains Hans-Florian Zeilhofer, surgeon and Delegate for Innovation at the University of Basel, who was also Co-Director of the first project phase together with Philippe Cattin.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.